Literature DB >> 6708930

Albumin binding of anti-inflammatory drugs. Utility of a site-oriented versus a stoichiometric analysis.

B Honoré, R Brodersen.   

Abstract

Binding equilibria of 12 nonsteroidal, anti-inflammatory substances, salicylic acid, diflunisal, phenylbutazone, azapropazone, fenbufen, biphenylacetic acid, naproxen, flurbiprofen, ibuprofin, diclofenac, indomethacin, and benoxaprofen, to defatted human serum albumin has been investigated at 37 degrees, pH 7.4, in a sodium phosphate buffer, 66 mM, by means of equilibrium dialysis and, in case of salicylic acid, by dialysis rate determinations. Cobinding of each of these drugs with monoacetyl-4,4'-diaminodiphenyl sulfone, warfarin, and diazepam has been studied by measuring dialysis rates of the last-mentioned ligands. Cobinding of each drug with bilirubin was investigated by two techniques, equilibrium dialysis against albumin with and without bilirubin, and by measuring rates of oxidation of free bilirubin with hydrogen peroxide and peroxidase. Results were analyzed in quantitative terms. The use of a site-oriented description versus a stoichiometric analysis is discussed. The stoichiometric description is preferred for the following reasons: (a) Simple relations exist between the percentage of bound drug at low drug concentrations and the first stoichiometric binding constant. (b) The stoichiometric description does not imply that preformed binding sites are present in the albumin molecule. (c) A quantitative, stoichiometric analysis of multiple cobinding of two ligands is possible.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6708930

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  16 in total

1.  The in situ acetylation of an immobilized human serum albumin chiral stationary phase for high-performance liquid chromatography in the examination of drug-protein binding phenomena.

Authors:  T A Noctor; I W Wainer
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200

2.  Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease.

Authors:  Kevin A Strauss; Donna L Robinson; Hendrik J Vreman; Erik G Puffenberger; Graham Hart; D Holmes Morton
Journal:  Eur J Pediatr       Date:  2006-01-25       Impact factor: 3.183

3.  Rapid analysis of the interactions between drugs and human serum albumin (HSA) using high-performance affinity chromatography (HPAC).

Authors:  Hee Seung Kim; Irving W Wainer
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-05-24       Impact factor: 3.205

Review 4.  Clinical pharmacokinetics of ibuprofen. The first 30 years.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

5.  Species differences of serum albumins: I. Drug binding sites.

Authors:  T Kosa; T Maruyama; M Otagiri
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

6.  Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure.

Authors:  R Zini; D Morin; C Salvadori; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

7.  Binding of pyrimethamine to human plasma proteins and erythrocytes.

Authors:  A C Rudy; W J Poynor
Journal:  Pharm Res       Date:  1990-10       Impact factor: 4.200

Review 8.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

9.  Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo.

Authors:  P Kurtzhals; S Havelund; I Jonassen; B Kiehr; U D Larsen; U Ribel; J Markussen
Journal:  Biochem J       Date:  1995-12-15       Impact factor: 3.857

Review 10.  Clinical pharmacokinetics of flurbiprofen and its enantiomers.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.